Back to search

Article

Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response Phenotypes

2026-06-12

Abstract excerpt

<h4>Background</h4> Ovarian cancer (OC) exhibits substantial heterogeneity in response to platinum-based chemotherapy, resulting in variable clinical outcomes and frequent recurrence. Current biomarkers, including serum CA-125 kinetics and BRCA mutational status, incompletely predict therapeutic response. We investigated whether patient-derived organoids (PDOs) could functionally stratify chemotherapy sensitivity...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
06bcbfe6-5d8c-5a31-85e8-014ae12f114c
DOI
10.64898/2026.06.10.731260
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response PhenotypesDOI 10.64898/2026.06.10.731260
Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity
Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity
Ascites-Derived Organoids for Prediction of Treatment Response and Clinical Management in Ovarian Cancer: A Case ReportSemantic proximity
Longitudinal Prediction of Drug Response in High-Grade Serous Ovarian Cancer Organoid Cultures Aligning with Clinical ResponsesSemantic proximity
Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity
Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer PatientsSemantic proximity
Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancerSemantic proximity
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesSemantic proximity
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity
In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity
The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testingSemantic proximity
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseSemantic proximity
Select a neighboring publication to make it the new centre.